Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human cytomegalovirus Pentameric glycoprotein complex (HCMV Pentamer)
- Target
- HCMV Pentamer
- Molecular classification
- Viral glycoprotein complex, Receptor-binding complex, Viral entry complex
01
Overview
The Human cytomegalovirus Pentameric glycoprotein complex (HCMV Pentamer) is a heteropentameric membrane-proximal protein complex composed of five subunits: glycoprotein H (gH), glycoprotein L (gL), UL128, UL130, and UL131A. It is essential for HCMV infection of epithelial, endothelial, and certain myeloid lineage cells by binding to host entry receptors, notably neuropilin-2 (NRP2). The Pentamer is a major target for potent virus-neutralizing antibodies and is central to vaccine and antibody therapeutic development. Disruption of the Pentamer or its interaction with cellular receptors can prevent HCMV cell entry, making it a validated antiviral target. It is distinct from the gH/gL/gO trimeric complex, which mediates entry into fibroblasts[2][3][4][6][9][8].
- Other names
- Pentameric complexHCMV PentamergH/gL/UL128–131 complexgH/gL/UL128/UL130/UL131A complex
02
Mechanism of action
Blockade of viral attachment and entry (by neutralizing antibodies or vaccines), Inhibition of receptor binding (neuropilin-2, NRP2), Potential interference with assembly or function
03
Biological functions
Viral entry and fusionHost cell tropism determinationImmune evasion (antibody target)Mediates infection of epithelial, endothelial, and myeloid cells
04
Disease associations
Infection (cytomegalovirus disease)Congenital cytomegalovirus infectionImmunocompromised host infections (e.g., transplant, HIV/AIDS)
05
Safety considerations
Immune escape mutationsglycosylation heterogeneity impacting antibody recognitionlimited host expression (as a viral target, human safety concerns are minimal, but risk of immune response to vaccination or therapy must be considered)
06
Interacting drugs
Letermovir (indirectly, as a CMV drug; direct interaction unclear)
2 more in the full profile.
07
Biomarkers
Neutralizing antibody titers against Pentamer (for vaccine efficacy or immune monitoring)
Beyond the preview
Go deeper on Human cytomegalovirus Pentameric glycoprotein complex (HCMV Pentamer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human cytomegalovirus Pentameric glycoprotein complex (HCMV Pentamer).